Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Jul;7(4):540-8.
doi: 10.1128/CDLI.7.4.540-548.2000.

Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation

Affiliations

Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation

J L Fahey et al. Clin Diagn Lab Immunol. 2000 Jul.

Abstract

An external evaluation program for measuring the performance of laboratories testing for cytokines and immune activation markers in biological fluids was developed. Cytokines, chemokines, soluble cytokine receptors, and other soluble markers of immune activation (CSM) were measured in plasma from a healthy human immunodeficiency virus (HIV)-seronegative reference population and from HIV-seropositive individuals as well as in supernatant fluids from in vitro-stimulated human immune cells. The 14 components measured were tumor necrosis factor (TNF) alpha, gamma interferon, interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-10, Rantes, MIP-Ia, MIP-Ibeta, soluble TNF receptor II, soluble IL-2 receptor alpha, beta(2)-microglobulin, and neopterin. Twelve laboratories associated with the Adult and Pediatric AIDS Clinical Trial Groups participated in the study. The performance features that were evaluated included intralaboratory variability, interlaboratory variability, comparison of reagent sources, and ability to detect CSM in the plasma of normal subjects as well as the changes occurring in disease. The principal findings were as follows: (i) on initial testing, i.e., before participating in the program, laboratories frequently differed markedly in their analytic results; (ii) the quality of testing of a CSM in individual participating laboratories could be assessed; (iii) most commercial kits allowed distinction between normal and abnormal plasma CSM levels and between supernatants of stimulated and unstimulated cells; (iv) different sources of reagents and reference standards frequently provided different absolute values; (v) inexperienced laboratories can benefit from participating in the program; (vi) laboratory performance improved during active participation in the program; and (vii) comparability between analyses conducted at different sites can be ensured by an external proficiency testing program.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Analytic data from study I for neopterin (A), sTNF-RII (B), and TNF-α (C) measured in several laboratories (designated by capital letters). Three aliquots (triplicates) of plasma (samples 1, 4, and 5) from a single seronegative donor were included, and the data are grouped on the left. Results for three plasma samples (samples 2, 3, and 6) from different HIV-seropositive donors are presented on the right.
FIG. 2
FIG. 2
Mean levels of cytokines, chemokines, and soluble products of immune activation reported by individual laboratories (designated by capital letters). Mean levels from triplicate samples of normal plasma in study I (A) and supernatant fluid from PHA-stimulated PBMC in study III (B) are presented for the laboratories that reported data. Assay values for all analytes are in picograms per milliliter.
FIG. 3
FIG. 3
Analytic data from study II for IFN-γ (A), TNF-α (B), IL-2 (C), and Rantes (D) measured in several laboratories (designated by capital letters). Three replicate sample (triplicate samples 1, 4, and 8) obtained from a PHA-stimulated 72-h supernatant are grouped on the left. Four samples (samples 2, 3, 6, and 9) were not stimulated. One PHA-stimulated whole blood supernatant (sample 7) and two LPS-stimulated cell supernatants, one from PBMC (sample 5) and one from whole blood (sample 10), are included. K and K′ designate results from laboratory K using two different reagent sources.
FIG. 4
FIG. 4
Analytic data from study III for TNF-α (A), IFN-γ (B), and Rantes (C) measured in several laboratories (designated by capital letters). Three replicates of a stimulated PBMC supernatant (samples 1, 3, and 5) are grouped on the left. Three other supernatants (stimulated [samples 2 and 6] and nonstimulated [sample 4]) are presented. C and C′ designate results from laboratory C using two different reagent sources.

Similar articles

Cited by

References

    1. Aziz N, Nishanian P, Fahey J L. Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures. Clin Diagn Lab Immunol. 1998;5:755–761. - PMC - PubMed
    1. Aziz N, Nishanian P, Mitsuyasu R, Detels R, Fahey J L. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol. 1999;6:89–95. - PMC - PubMed
    1. Bienvenu J, Coulon L, Doche C, Gutowski M C, Grau G. Analytical performances of commercial ELISA kits for IL-2, IL-6 and TNFα. A WHO study. Eur Cytokine Netw. 1993;4:447–451. - PubMed
    1. DeKossodo S, Houba V, Grau G E WHO Collaborative Study Group. Assaying tumor necrosis factor concentration in human serum. A WHO international collaborative study. J Immunol Methods. 1995;182:107–114. - PubMed
    1. Fahey J L, Taylor J M G, Manna B, Nishanian P, Aziz N, Giorgi J V, Detels R. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12:1581–1590. - PubMed

Publication types